Troxerutin is a novel osmotic agent for peritoneal dialysis with protective cardiovascular actions

End-stage renal disease patients require peritoneal dialysis (PD) as a life-saving therapy; however, they continue to experience systemic inflammation and increased cardiovascular pathology. These complications can be exacerbated by exposure to PD solutions (PDS) containing glucose. This highlights...

Full description

Bibliographic Details

Published in:	Nephrology, dialysis, transplantation
Main Authors:	Kopytina, Valeria, Marchant, Vanessa, Rodrigues-Diez, Raquel, Pascual-Antón, Lucía, Toggweiler, Nora, Strahl, Lisa, Kane, Jamie, Tejera-Muñoz, Antonio, Cortés, Marcelino, Sucunza, David, Vaquero, Juan J, Vervloet, Marc, Piecha, Dorothea, Eringa, Etto C, Ruiz-Ortega, Marta, López-Cabrera, Manuel, González-Mateo, Guadalupe T
Format:	Journal Article
Language:	English
Published:	England 13.11.2025
Subjects:	cardiovascular disease peritoneal dialysis osmotic agent biocompatibility kidney replacement therapy
ISSN:	1460-2385, 1460-2385
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!